Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0000899243-22-030438
Filing Date
2022-09-06
Accepted
2022-09-06 17:06:32
Documents
2
Period of Report
2022-09-01

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 1587
2 EX-24 DOCUMENT attachment1.htm EX-24 2912
  Complete submission text file 0000899243-22-030438.txt   5897
Mailing Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339
Business Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339 678-392-3419
Inhibikase Therapeutics, Inc. (Issuer) CIK: 0001750149 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address C/O CYTEK BIOSCIENCES, INC. 46107 LANDING PARKWAY FREMONT CA 94538
Business Address
Dion Gisele (Reporting) CIK: 0001873088 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-39676 | Film No.: 221228985